Advanced Search

Technical Analysis for ATNX - Athenex, Inc.

Grade Last Price % Change Price Change
grade F 11.66 5.90% 0.65
ATNX closed up 0.09 percent on Friday, August 7, 2020, on 1.23 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
2 Watchers
Watchlist Portfolio

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Up
Historical ATNX trend table...
Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 5.90%
NR7 Range Contraction 5.90%
Earnings Movers Other 5.90%
Inside Day Range Contraction 5.90%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 6.00%
Earnings Movers Other 6.00%
Outside Day Range Expansion 6.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 2.28%
Up 3 Days in a Row Strength 2.28%
Spinning Top Other 3.74%
Older EOD signals for ATNX ...
View Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Get Started for Free!
Configure default chart indicators Basic chart:

Profile

Athenex, Inc. is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company's technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics. The Company offers Oraxol, an oral formulation of paclitaxel; Orateacan, an oral formulation of Irinotecan; Oradoxel, an oral formulation of Docetaxel, and an oral formulation of Topotecan for the treatment of various types of cancers. Its Src Kinase Inhibitors include KX-01 (KX2-391) and KX-02 (KX2-361) oncology drug candidates. The Company's Symptom Therapeutics include CQ-01, which is used for the treatment of burn pruritus and scars; CQ-R1, which is used for the treatment of an irradiation-induced dermatitis, and an intranasal Granisetron used for the treatment of chemotherapy-induced nausea/vomiting.
Chemistry Oncology Cancers Organic Compounds Chemotherapy Antineoplastic Drugs Organic Chemistry Therapies For Cancer Docetaxel Pruritus Scars Treatment Of Various Types Of Cancers

Is ATNX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

Recent News

Date Title
Aug 9 Athenex, Inc. (ATNX) CEO Johnson Lau on Q2 2020 Results - Earnings Call Transcript
Aug 7 Athenex (ATNX) Investor Presentation - Slideshow
Aug 7 Is Athenex, Inc. (NASDAQ:ATNX) Popular Amongst Insiders?
Aug 6 Athenex (ATNX) Reports Q2 Loss, Tops Revenue Estimates
Aug 6 The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Bristol-Myers Squibb Earnings, Acutus Medical IPO
Aug 6 Athenex EPS in-line, beats on revenue
Aug 6 Athenex, Inc. Reports Second Quarter Ended June 30, 2020 Financial Results and Provides Corporate Update
Aug 6 Athenex Announces $50 Million Revenue Interest Financing with Sagard Healthcare Royalty Partners
Aug 4 Biopharmaceutical Leader Robert J. Spiegel, MD, FACP Appointed to the Athenex Board of Directors
Aug 2 The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings
See more ATNX news...

Indicators

Indicator Value
52 Week High 18.35
52 Week Low 5.63
Average Volume 567,882
200-Day Moving Average 12.18
50-Day Moving Average 12.29
20-Day Moving Average 11.56
10-Day Moving Average 11.06
Average True Range 0.60
ADX 23.39
+DI 14.35
-DI 22.81
Chandelier Exit (Long, 3 ATRs ) 11.78
Chandelier Exit (Short, 3 ATRs ) 12.20
Upper Bollinger Band 12.77
Lower Bollinger Band 10.36
Percent B (%b) 0.27
BandWidth 20.86
MACD Line -0.39
MACD Signal Line -0.35
MACD Histogram -0.0365
Fundamentals Value
Market Cap 628.27 Million
Num Shares 57.1 Million
EPS -3.47
Price-to-Earnings (P/E) Ratio -3.17
Price-to-Sales 47.88
Price-to-Book 7.97
PEG Ratio 0.98
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 11.46
Resistance 3 (R3) 11.44 11.27 11.39
Resistance 2 (R2) 11.27 11.16 11.28 11.36
Resistance 1 (R1) 11.14 11.08 11.21 11.16 11.33
Pivot Point 10.97 10.97 11.00 10.98 10.97
Support 1 (S1) 10.84 10.86 10.91 10.86 10.69
Support 2 (S2) 10.67 10.78 10.68 10.66
Support 3 (S3) 10.54 10.67 10.64
Support 4 (S4) 10.56